Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Tislelizumab in Microsatellite instability-high colorectal cancer: NCT04802876 Clinical Landscape Report 2026
28 September 2026
NCT04802876 clinical landscape for Microsatellite instability-high colorectal cancer: endpoints, sponsor, phase, geography, readouts, asset context and devel…
9 min read
Viltolarsen in Muscular Dystrophy, Duchenne: NCT04687020 Clinical Landscape Report 2026
28 September 2026
NCT04687020 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Golodirsen in Muscular Dystrophy, Duchenne: NCT04708314 Clinical Landscape Report 2026
28 September 2026
NCT04708314 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Malignant Pleural Mesothelioma: NCT04713761 Clinical Landscape Report 2026
28 September 2026
NCT04713761 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Porfimer Sodium in Malignant Pleural Mesothelioma: NCT04836429 Clinical Landscape Report 2026
28 September 2026
NCT04836429 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Malignant Pleural Mesothelioma: NCT04897022 Clinical Landscape Report 2026
28 September 2026
NCT04897022 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IAG-933 in Unresectable Pleural Malignant Mesothelioma: NCT04857372 Clinical Landscape Report 2026
28 September 2026
NCT04857372 clinical landscape for Unresectable Pleural Malignant Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
LMB-100 in Mesothelioma, Malignant: NCT04840615 Clinical Landscape Report 2026
28 September 2026
NCT04840615 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mitomycin in Malignant Mesothelioma of Peritoneum: NCT04847063 Clinical Landscape Report 2026
28 September 2026
NCT04847063 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Pembrolizumab in Glioblastoma: NCT04913337 Clinical Landscape Report 2026
28 September 2026
NCT04913337 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
WVE-N531 in Muscular Dystrophy, Duchenne: NCT04906460 Clinical Landscape Report 2026
28 September 2026
NCT04906460 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IBI-323 in Advanced Bile Duct Carcinoma: NCT04916119 Clinical Landscape Report 2026
28 September 2026
NCT04916119 clinical landscape for Advanced Bile Duct Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.